Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease (2019)
Type of ContentJournal Article
PublisherFrontiers Media SA
- Science: Journal Articles 
The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET imaging to test for any association between cerebral amyloid deposition and cognitive impairment in PD, in a sample enriched for cases with mild cognitive impairment. This cross-sectional study used Movement Disorders Society level II criteria to classify 115 participants with PD as having normal cognition (PDN, n = 23), mild cognitive impairment (PD-MCI, n = 76), or dementia (PDD, n = 16). We acquired 18F-Florbetaben (FBB) amyloid PET and structural MRI. Amyloid deposition was assessed between the three cognitive groups, and also across the whole sample using continuous measures of both global cognitive status and average performance in memory domain tests. Outcomes were cortical FBB uptake, expressed in centiloids and as standardized uptake value ratios (SUVR) using the Centiloid Project whole cerebellum region as a reference, and regional SUVR measurements. FBB binding was higher in PDD, but this difference did not survive adjustment for the older age of the PDD group. We established a suitable centiloid cut-off for amyloid positivity in Parkinson's disease (31.3), but there was no association of FBB binding with global cognitive or memory scores. The failure to find an association between PET amyloid deposition and cognitive impairment in a moderately large sample, particularly given that it was enriched with PD-MCI patients at risk of dementia, suggests that amyloid pathology is not the primary driver of cognitive impairment and dementia in most patients with PD.
CitationMelzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Grenfell S, Horne KL, Young BN, Pascoe MJ, Almuqbel MM, Wang J, Marsh SH, Miller DH, Dalrymple-Alford JC, Anderson TJ (2019). Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease. Frontiers in Neurology. 10(APR). 391-.
This citation is automatically generated and may be unreliable. Use as a guide only.
KeywordsParkinson's disease; amyloid PET; Florbetaben; dementia; centiloid; mild cognitive impairment
ANZSRC Fields of Research32 - Biomedical and clinical sciences::3209 - Neurosciences::320905 - Neurology and neuromuscular diseases
32 - Biomedical and clinical sciences::3202 - Clinical sciences::320206 - Diagnostic radiography
52 - Psychology::5202 - Biological psychology::520203 - Cognitive neuroscience
52 - Psychology::5202 - Biological psychology::520206 - Psychophysiology
RightsCopyright © 2019 Melzer, Stark, Keenan, Myall, MacAskill, Pitcher, Livingston, Grenfell, Horne, Young, Pascoe, Almuqbel, Wang, Marsh, Miller, Dalrymple- Alford and Anderson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Showing items related by title, author, creator and subject.
Changes of plasma cGP/IGF-1 molar ratio with age is associated with cognitive status of Parkinson disease Fan D; MacAskill M; Anderson T; Guan J; Dalrymple-Alford, John; Pitcher, Toni (Wiley, 2020)Objective: Cognitive impairment is a common feature of Parkinson disease (PD), for which age is a major contributing factor. Insulin-like growth factor-1 (IGF-1) declines with age and contributes to age-related cognitive ...
Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability Botía J; Nalls MA; Noyce AJ; Nicolas A; Cookson MR; Bandres-Ciga S; Gibbs JR; Hernandez DG; Singleton AB; Reed X; Leonard H; Blauwendraat C; Faghri F; Bras J; Guerreiro R; Tucci A; Kia DA; Houlden H; Plun-Favreau H; Mok KY; Wood NW; Lovering R; R’Bibo L; Rizig M; Chelban V; Trabzuni D; Tan M; Morris HR; Middlehurst B; Quinn J; Billingsley K; Holmans P; Kinghorn KJ; Lewis P; Escott-Price V; Williams N; Foltynie T; Brice A; Danjou F; Lesage S; Corvol JC; Martinez M; Giri A; Schulte C; Brockmann K; Simón-Sánchez J; Heutink P; Gasser T; Rizzu P; Sharma M; Shulman JM; Robak L; Lubbe S; Mencacci NE; Finkbeiner S; Lungu C; Scholz SW; Gan-Or Z; Rouleau GA; Krohan L; van Hilten JJ; Marinus J; Adarmes-Gómez AD; Bernal-Bernal I; Bonilla-Toribio M; Buiza-Rueda D; Carrillo F; Carrión-Claro M; Mir P; Gómez-Garre P; Jesús S; Labrador-Espinosa MA; Macias D; Vargas-González L; Méndez-del-Barrio C; Periñán-Tocino T; Tejera-Parrado C; Diez-Fairen M; Aguilar M; Alvarez I; Boungiorno MT; Carcel M; Pastor P; Tartari JP; Alvarez V; González MM; Blazquez M; Garcia C; Suarez-Sanmartin E; Barrero FJ; Rezola EM; Yarza JAB; Pagola AG; de Munain Arregui AL; Ruiz-Martínez J; Cerdan D; Duarte J; Clarimón J; Dols-Icardo O; Reynolds, Regina (Springer Science and Business Media LLC, 2019)Parkinson’s disease (PD), with its characteristic loss of nigrostriatal dopaminergic neurons and deposition of α-synuclein in neurons, is often considered a neuronal disorder. However, in recent years substantial evidence ...
Supplementation of blackcurrant anthocyanins increased cyclic glycine-proline in the cerebrospinal fluid of parkinson patients: Potential treatment to improve insulin-like growth factor-1 function Fan D; Alamri Y; Liu K; Macaskill M; Harris P; Brimble M; Prickett T; Menzies O; Laurenson A; Anderson T; Guan J; Dalrymple-Alford, John (MDPI AG, 2018)Background: Insulin-like growth factor-1 (IGF-1) function is impaired in Parkinson disease. Cyclic glycine-proline (cGP), a metabolite of IGF-1, is neuroprotective through improving IGF-1 function. Parkinson disease patients ...